Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
4:46 PM ET 2/19/25 | BusinessWire
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
EMERYVILLE, Calif.--(BUSINESS WIRE)--February 19, 2025--
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC ("D. Boral Capital"), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00.
Valuation Highlights
-- D. Boral Capital's analysis focuses on the development of EB103 in B-cell
Non-Hodgkin's Lymphoma, emphasizing Estrella's ARTEMIS(R) T-cell
engineering platform that utilizes cellular mechanisms which closely
resemble those of endogenous T-cell receptors, producing a more natural
and regulated immune response.
-- The derived 12-month price target of $16.00 underscores market confidence
in Estrella's potential to capture significant market share in
immuno-oncology.
-- The models incorporate a 30% probability of success along with a 30%
discount rate, reflecting the early stage of Estrella's clinical
development.